• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

ICER Finds ‘Substantial Uncertainties’ in Lykos’ MDMA Trials Ahead of Adcomm

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 16, 2024 at 12:02: PM
via Due to concerns of study bias, the Institute for Clinical and Economic Review on Tuesday said in a draft report that it is unable to accurately assess the net benefit of Lykos Therapeutics’ investigational MDMA-assisted therapy in post-traumatic stress disorder.

article source
 




Top Bottom
Back
Quote